Fig. 4: In-depth evaluation of biomarker performance according to tumour histology and stage and expression change relative to surgical treatment.
From: A blood-based transcriptomic signature for noninvasive diagnosis of gastric cancer
The diagnostic performance of the biomarker was assessed according to tumour histology (diffuse vs. intestinal type) and stage (stage 1 and 2 vs. 3 and 4). a In the clinical training cohort, regardless of histology, the biomarker consistently identified patients with GC. In addition, the diagnostic performance in patients with stage 1 and 2 tumours was remarkable. b In the clinical validation cohort, the robust performance of the biomarker was again demonstrated relative to tumour histology and pathologic stage. c Compared to preoperative gene expression, three genes (HBB, ISG15, and KRT7) were significantly downregulated after curative surgery in patients with diffuse-type GC. (**P < 0.01, *P < 0.05, n.s.: not significant).
